A group of investors advised by Munich-based Rigeto Unternehmerkapital has acquired prevention-center as an add-on to the Matignon Group. Prevention-center is a leading Swiss provider of cosmetic, medical and aesthetic services in the field of
Tags :Vischer
Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital,
ATANIS Biotech, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and
Intel Capital, an investor in the future of compute, has invested in Unisers, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials. The USD14 million seed financing round was led
Geneva-based cybersecurity firm e-Xpert Solutions and the Vaud-based One Step Beyond Group, both specialized in consulting and cloud integration, have merged under a new structure called Swiss Expert Group. Vischer acted as counsel to One
BlackSheep MadTech Fund, managed by EUREKA! Venture SGR, the first European venture capital fund with an entrepreneurial background that invests in the marketing and advertising technology industry, has been the lead investor in the USD 5
Huntsman Corporation closed the sale of its Textile Effects division to Archroma, a portfolio company of SK Capital Partners, on February 28, 2023. The agreed purchase price was $593 million in cash plus assumed pension liabilities, and Huntsman
Medartis, a Basel-based orthopedic company specializing in head and extremity surgery, recently signed an agreement with the private founders of KeriMedical, a Geneva-based private company specializing in the development and manufacture of implants for hand
Basel-based orthopedic firm, Medartis, has successfully completed the acquisition of an additional 18% stake in Geneva-based implant manufacturer, KeriMedical, for approximately CHF 18 million. This deal will raise Medartis’ stake to 47%, further cementing the company’s commitment
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
